February session to highlight how Zomedica's R&D strategy supports scalable growth and long-term shareholder value ANN ARBOR, MI / ACCESS Newswire / February 5, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced the next installment of its "Fourth Friday at Four" investor webinar series, scheduled for Friday, February 27, 2026 at 4:00 p.m. Eastern Time. ...

Group 1 - The webinar is focused on Zomedica's technology innovation and aims to provide insights into the company's product platforms and the team driving its success [1][2] - The presentation includes forward-looking statements regarding future expectations, plans, and prospects, emphasizing the potential for actual results to differ [1][2] - The company expresses excitement about engaging with current and potential investors to enhance their understanding of the value delivered to veterinarians and shareholders [2] Group 2 - Larry Heaton, the Chief Executive Officer of Zomedica, is set to present during the webinar, indicating leadership involvement in communicating the company's vision [3]

Summary of Zomedica's Investor Webinar Company Overview - **Company**: Zomedica - **Industry**: Animal Health - **Focus**: Advancing animal health through technology and digital innovation, enhancing veterinary practices, and improving clinical outcomes for pets and their owners [2][3] Core Points and Arguments 1. **Technological Advancements** - The animal health industry is experiencing significant changes due to advancements in diagnostics, connectivity, and artificial intelligence (AI) [3] - Zomedica is investing in connected devices, cloud platforms, and AI to enhance veterinary care [3][6] 2. **Five Pillars of Zomedica's Mission** - **Quality of Care**: Improve pet care quality [5] - **Pet Parent Satisfaction**: Enhance confidence and comfort for pet owners [5] - **Veterinarian Workflow**: Streamline daily operations for veterinarians [5] - **Veterinarian Cash Flow**: Ensure financial accessibility of offerings [5] - **Profitability**: Increase profitability for veterinary clinics [5] 3. **Market Trends** - Investment in AI in animal health is projected to grow from $1.57 billion in 2024 to nearly $7 billion by 2033, with an 18% CAGR [9] - The global pet technology market is expected to rise from $7.6 billion in 2024 to over $17 billion by 2033 [9] - The veterinary telehealth market is forecasted to grow from approximately $620 million in 2024 to $3.2 billion by 2034, also an 18% CAGR [10] 4. **Digital Transformation Journey** - Zomedica has launched several platforms, including MyZomedica and TRUFORMA, to enhance customer experience and product integration [12][14] - The company has developed a mobile app to support training and maximize revenue from its products [13] 5. **AI Integration and Data Utilization** - Zomedica is leveraging AI for improved diagnostics and clinical decision support, enhancing the veterinarian-pet parent relationship [11][24] - The company is building a data foundation to support AI solutions, which will drive long-term value [24][25] 6. **PIMS Integration** - Zomedica plans to integrate its products with Patient Information Management Systems (PIMS) by the end of Q2 2026, enhancing workflow and convenience for veterinary clinics [41][43] 7. **Financial Outlook** - Zomedica anticipates reaching break-even with an annualized revenue of $55 million by 2027 [36][56] - The company expects to report its first revenue from a collaboration with Rahm Sensor in Q1 2026 [30][31] Other Important Content - Zomedica's manufacturing capacity is sufficient to meet demand without requiring additional capital expenditure [32] - The company is focused on maintaining margins while driving revenue growth and reducing operating expenses [56][57] - Zomedica is exploring partnerships with larger companies and expanding its presence in the equine market [40][62] Conclusion Zomedica is positioned to capitalize on the growing trends in the animal health industry through its innovative technology and digital strategies. The company's focus on improving veterinary practices and enhancing pet care is expected to drive long-term growth and shareholder value.

Core Insights - Zomedica Corp. has entered into a contract manufacturing and service agreement with Rahm Sensor Development to produce the Cell-Guardian™, a personnel monitoring device aimed at enhancing safety in high-risk environments [1] Group 1: Agreement Details - The agreement allows Zomedica to leverage existing infrastructure to generate contract-based revenue [1] - It aims to improve asset utilization and support long-term cash flow [1] - The partnership is expected to create shareholder value through diversification into new markets [1] Group 2: Product Information - The Cell-Guardian™ is designed to provide advanced monitoring solutions for personnel in high-risk environments [1] - This product represents Rahm's first commercial offering in the market [1]

Core Viewpoint - Zomedica Corp. is enhancing its digital capabilities and long-term innovation strategy, as highlighted in its upcoming investor webinar scheduled for January 23, 2026 [1] Group 1 - Zomedica is an animal health company focused on innovative diagnostic and therapeutic devices for equine and companion animals [1] - The company will host the next session of its "Fourth Friday at Four" investor webinar series on January 23, 2026, at 4:00 p.m. Eastern Time [1]

Core Viewpoint - Zomedica Corp. has launched the VETGuardian PLUS monitor, enhancing its Zero Touch™ patient monitoring platform for veterinary clinics, aimed at improving workflow efficiency and clinical confidence while supporting long-term growth strategy [1] Group 1: Product Launch - The VETGuardian PLUS monitor is the next generation of the original VETGuardian® system [1] - New features have been added to improve ease of use and access to patient data [1] Group 2: Company Strategy - The launch of the VETGuardian PLUS monitor aligns with Zomedica's long-term growth strategy [1] - The product aims to strengthen clinical confidence in veterinary practices [1]

Core Viewpoint - Zomedica Corp. is hosting a special session of its "Fourth Friday at Four" investor webinar series to provide strategic context for its product platforms, with the session scheduled for November 21, 2025 [1] Group 1 - The webinar will take place on the third Friday of November to accommodate the holiday calendar [1] - The session aims to highlight Zomedica's innovative diagnostic and therapeutic devices for equine and companion animals [1]

Core Insights - Zomedica Corp. has achieved ISO 13485:2016 certification for its manufacturing and distribution operations, enhancing its commitment to quality and compliance [1] Company Summary - The certification applies to Zomedica's facilities in Plymouth, Minnesota, and Roswell, Georgia, reinforcing the company's operational standards [1] - This milestone supports Zomedica's long-term growth strategy and readiness for global markets [1]

Revenue Growth - Revenue for Q3 2025 increased by 16% to $8.1 million, marking the highest quarterly revenue in company history and the 19th consecutive quarter of year-over-year revenue growth[1][10][12]. - The Diagnostics segment saw a significant growth of 51%, driven by the adoption of the TRUFORMA® platform and the introduction of a new Development Services revenue stream[5][10][16]. - International sales grew by 16% year-over-year, supported by new distribution agreements and partnerships in key markets[6]. - The introduction of new products, including enhancements to the TRUFORMA® platform and the upcoming TRUVIEW AI platform, is expected to drive future revenue growth[7]. - Zomedica's total addressable market in the U.S. exceeds $2 billion, indicating significant growth opportunities in the animal health sector[21]. Profitability and Expenses - Gross margin for the quarter was reported at 67%, contributing to improved profitability prospects[8][10][13]. - Operating expenses decreased by 4% year-over-year to $12.0 million, reflecting effective cost-reduction initiatives[8][13][14]. - Net loss for Q3 2025 was reduced by 9% to $6.1 million compared to the same period in 2024[15]. - Adjusted Non-GAAP EBITDA loss for the three months ended September 30, 2025, was $3,702 thousand, an improvement from $4,313 thousand in the same period of 2024[31]. - Interest income for the three months ended September 30, 2025, was $(561) thousand, an improvement from $(977) thousand in 2024[31]. Financial Position - The company had cash and cash equivalents of $54.4 million as of September 30, 2025, providing a strong liquidity position to support growth initiatives[18]. - Non-GAAP EBITDA loss for the nine months ended September 30, 2025, was $71,427 thousand, compared to a loss of $34,612 thousand in 2024, indicating a significant increase in losses[33]. - Total net loss for the nine months ended September 30, 2025, reached $77,223 thousand, compared to $39,536 thousand in 2024, reflecting a worsening financial position[33]. Impairment and Expenses - Impairment expense for the nine months ended September 30, 2025, was $55,833 thousand, a substantial increase from $16,024 thousand in 2024[33]. - Stock-compensation expense for the three months ended September 30, 2025, was $868 thousand, up from $473 thousand in the same period of 2024[31]. - Amortization expense for the nine months ended September 30, 2025, was $4,499 thousand, slightly lower than $4,834 thousand in 2024[33]. - Income tax benefit for the nine months ended September 30, 2025, was $(64) thousand, compared to $(336) thousand in 2024, indicating a decrease in tax benefits[33]. Proforma Adjustments - Proforma adjustments for the three months ended September 30, 2025, included $214 thousand, down from $523 thousand in 2024[31].

Core Insights - Zomedica reported its highest quarterly revenue ever for the third quarter ended September 30, 2025, marking a record year-over-year revenue for the 19th consecutive quarter [1] Financial Performance - The company achieved significant financial growth, with consolidated financial results indicating a strong performance in the animal health sector [1] - The report highlights the effectiveness of Zomedica's point-of-care diagnostic and therapeutic products for equine and companion animals, contributing to the revenue increase [1]